046210 — HLB PanaGene Co Balance Sheet
0.000.00%
- KR₩154bn
- KR₩104bn
- KR₩12bn
Annual balance sheet for HLB PanaGene Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 6,137 | 11,963 | 17,611 | 19,947 | 76,852 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,724 | 3,403 | 2,510 | 2,795 | 3,004 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 10,114 | 18,567 | 23,444 | 26,014 | 82,900 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8,437 | 7,725 | 7,298 | 7,029 | 7,338 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 21,787 | 27,232 | 31,909 | 34,673 | 90,914 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 489 | 982 | 794 | 1,419 | 27,134 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,582 | 2,162 | 2,066 | 2,984 | 27,341 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 20,205 | 25,070 | 29,844 | 31,689 | 63,573 |
Total Liabilities & Shareholders' Equity | 21,787 | 27,232 | 31,909 | 34,673 | 90,914 |
Total Common Shares Outstanding |